View More View Less
  • 1 Óbuda Hypertonia Centrum Budapest Vörösvári út 9., II. 8. 1035
  • 2 Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika, Geriátriai Tanszéki Csoport Budapest
  • 3 Szent Imre Egyetemi Oktatókórház Nephrologia-Hypertonia Profil és Aktív Geriátria Részleg Budapest
  • 4 B.Braun Avitum Dialízis Hálózat 1. sz. Dialízisközpont Budapest
Open access

A szerzők összefoglalják és elemzik a vérnyomás-variabilitásról szóló irodalmi adatokat. Bemutatják a vérnyomás-variabilitás mérési típusait, azok klinikai értékét, összefüggésüket a szervi károsodásokkal és a cardiovascularis események megjelenésének kockázatával. Jellemzik a prognosztikai értékre vonatkozó adatokat és áttekintik a különböző antihipertenzív szereknek a vérnyomás-variabilitásra kifejtett hatásait. Véleményük szerint ma már bizonyítottnak tekinthető, hogy a hypertonia kezelése során a vérnyomáscélérték elérése mellett törekedni kell a vérnyomás-variabilitás csökkentésére, a vérnyomás-fluktuáció befolyásolására, mert ez jelenti az egyik legnagyobb veszélyt a hypertoniás egyén számára. Beszámolnak a hazai tapasztalatokról is. Reményteljesnek tartják, hogy a nemzetközi irányelvekben a vérnyomás-variabilitás mérése teret nyert. Orv. Hetil., 2014, 155(42), 1661–1672.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Chobanian, A. V., Bakris, G. L., Black, H. R., et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 2003, 42(6), 1206–1252.

  • Parati, G., Bilo, G., Valentini, M.: Blood pressure variability: methodological aspects, pathophysiological and clinical implications. In: Mancia, G., Grassi, G., Kjeldsen, S. E. (eds.): Manual of Hypertension of the European Society of Hypertension, Informa Healthcare, London, 2008.

  • Mancia, G., Ferrari, A., Gregorini, L., et al.: Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ. Res., 1983, 53(1), 96–104.

  • Parati, G., Ochoa, J. E., Bilo, G.: Blood pressure variability, cardiovascular risk, and risk for renal disease progression. Curr. Hypertens. Rep., 2012, 14(5), 421–431.

  • Rothwell, P. M., Howard, S. C., Dolan E., et al.: Effects of beta-blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol., 2010, 9(5), 469–480.

  • Höcht, C.: Blood Pressure Variability: Prognostic Value and Therapeutic Implications. Hindawi Publishing Corporation, ISRN Hypertension, 2013, http://dx.doi.org/10.5402/2013/398485

  • Parati, G., Ochoa, J. E., Lombardi, C., et al.: Assessment and management of blood-pressure variability. Nat. Rev. Cardiol., 2013, 10(3), 143–155.

  • Stauss, H. M.: Identification of blood pressure control mechanisms by power spectral analysis. Clin. Exp. Pharmacol. Physiol., 2007, 34(4), 362–368.

  • Langager, A. M., Hammerberg, B. E., Rotella, D. L., et al.: Very low-frequency blood pressure variability depends on voltage-gated L-type Ca2+ channels in conscious rats. Am. J. Physiol., 2007, 292(3), H1321–H1327.

  • Souza, H. C., Martins-Pinge, M. C., Dias da Silva, V. J., et al.: Heart rate and arterial pressure variability in the experimental renovascular hypertension model in rats. Auton. Neurosci, 2008, 139(1–2), 38–45.

  • Fazan, R. Jr., Huber, D. A., Silva, C. A., et al.: Sildenafil acts on the central nervous system increasing sympathetic activity. J. Appl. Physiol., 2008, 104(6), 1683–1689.

  • Janssen, B. J., Oosting, J., Slaaf D. V., et al.: Hemodynamic basis of oscillations in systemic arterial pressure in conscious rats. Am. J. Physiol., 1995, 269(1), H62–H71.

  • Bertera, F. M., Del Mauro, J. S., Chiappetta, D., et al.: Enantioselective pharmacokinetic and pharmacodynamic properties of carvedilol in spontaneously hypertensive rats: focus on blood pressure variability. Naunyn-Schmiedeberg’s Arch. Pharmacol., 2012, 385(3), 325–335.

  • Bertera, F. M., Del Mauro, J. S., Lovera, V., et al.: Acute effects of third generation β-blockers on short-term and beat-to-beat blood pressure variability in sinoaortic-denervated rats. Hypertens. Res., 2013, 36(4), 349–355.

  • Shimbo, D., Shea, S., McClelland, R. L., et al.: Associations of aortic distensibility and arterial elasticity with long-term visit-to-visit blood pressure variability: the Multi-Ethnic Study of Atherosclerosis (MESA). Am. J. Hypertens., 2013, 26(7), 896–902.

  • García-García, A., García-Ortiz, L., Recio-Rodríguez, J. I., et al.: Relationship of 24-h blood pressure variability with vascular structure and function in hypertensive patients. Blood Press. Monitor, 2013, 18(2), 101–106.

  • Matsui, Y., Ishikawa, J., Eguchi, K., et al.: Maximum value of home blood pressure: a novel indicator of target organ damage in hypertension. Hypertension, 2011, 57(6), 1087–1093.

  • Mancia, G., Facchetti, R., Parati, G., et al.: Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment. J. Hypertens., 2012, 30(6), 1241–1251.

  • Masugata, H., Senda, S., Murao, K., et al.: Visit-to-visit variability in blood pressure over a 1-year period is a marker of left ventricular diastolic dysfunction in treated hypertensive patients. Hypertens. Res., 2011, 34(7), 846–850.

  • Nagai, M., Hoshide, S., Ishikawa, J., et al.: Visit-to-visit blood pressure variations: new independent determinants for carotid artery measures in the elderly at high risk of cardiovascular disease. J. Am. Soc. Hypertens., 2011, 5(3), 184–192.

  • Brickman, A. M., Reitz C., Luchsinger J. A., et al.: Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort. Arch. Neurol., 2010, 67(5), 564–569.

  • Mancia, G., Fagard, R., Narkiewicz, K., et al.: 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens., 2013, 31(7), 1281–1357.

  • Kiss, I., Kékes, E.: Application of telemedicine for increasing the proportion of patients who reach target blood pressure and for improving the quality of patient care. [A hypertoniás betegek célvérnyomás-elérési arányának és gondozási minőségének segítése telemedicinális lehetőségek alkalmazásával.] Hypertonia és Nephrologia, 2012, 16(6), 243–245. [Hungarian]

  • Mancia, G., Parati, G.: The role of blood pressure variability in end-organ damage. J. Hypertens., 2003, 21(6), S17–S23.

  • Hansen, T. W., Thijs, L., Li, Y., et al.: Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension, 2010, 55(4), 1049–1057.

  • Niiranen, T. J., Jula, A. M., Kantola, I. M., et al.: Comparison of agreement between clinic and home-measured blood pressure in the Finnish population: the Finn-HOME Study. J Hypertens., 2006, 24(8), 1549–1555.

  • Hata, Y., Kimura, Y., Muratani, H., et al.: Office blood pressure variability as a predictor of brain infarction in elderly hypertensive patients. Hypertens. Res., 2000, 23(6), 553–560.

  • Hata, Y., Muratani, H., Kimura, Y., et al.: Office blood pressure variability as a predictor of acute myocardial infarction in elderly patients receiving antihypertensive therapy. J. Hum. Hypertens., 2002, 16(2), 141–146.

  • Rothwell, P. M., Howard, S. C., Dolan, E., et al.: Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet, 2010, 375(9718), 895–905.

  • Mancia, G., Messerli, F., Bakris, G., et al.: Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension, 2007, 50(2), 299–305.

  • Warren, R. E., Marshall, T., Padfield, P. L., et al.: Variability of office, 24-hour ambulatory, and self-monitored blood pressure measurements. Br. J. Gen. Pract., 2010, 60(578), 675–680.

  • Liu, J. G., Xu, L. P., Chu, Z. X., et al.: Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. J. Hypertens., 2003, 21(10), 1961–1967.

  • Parati, G., Faini, A., Valentini, M.: Blood pressure variability: its measurement and significance in hypertension. Curr. Hypertens. Rep., 2006, 8(3), 199–204.

  • Parati, G., Omboni, S., Rizzoni, D., et al.: The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J. Hypertens., 1998, 16(11), 1685–1691.

  • Rizzoni, D., Muiesan, M. L., Salvetti, M., et al.: The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment. J. Hypertens., 2001, 19(4), 703–711.

  • Clement, D. L.: Blood presure variability as a new target. E-journal of the ESC Council for Cardiology Practice, 2011, 9, Jul, 22.

  • Wang, J., Shen, F. M., Wang, M. W., et al.: Effects of nine antihypertensive drugs on blood pressure variability in sinoaortic-denervated rats. Acta Pharmacol. Sin., 2006, 27(8), 1013–1017.

  • Bertera, F. M., Del Mauro, J. S., Polizio, A. H., et. al.: Effect of nebivolol on beat-to-beat and short-term blood pressure variability in spontaneously hypertensive rats. Naunyn-Schmiedeberg’s Arch Pharmacol, 2012, 385(8), 833–843.

  • Höcht, C., Bertera, F. M., Taira, C. A.: Importance of blood pressure variability in the assessment of cardiovascular risk and benefits of antihypertensive therapy. Expert Rev. Clin. Pharmacol., 2010, 3(5), 617–621.

  • Mancia, G., Facchetti, R., Parati, G., et al.: Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis. Circulation, 2012, 126(5), 569–578.

  • Webb, A. J., Fischer, U., Mehta, Z., et al.: Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and metaanalysis. Lancet, 2010, 375(9718), 906–915.

  • Masuda, S., Tamura, K., Wakui, H., et al.: Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. Hypertens. Res., 2009, 32(11), 950–955.

  • Shigenaga, A., Tamura, K., Dejima, T., et al.: Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis. Nephron Clin. Pract., 2009, 112(1), c31–c40.

  • Zhang, Y., Agnoletti, D., Safar, M. E., et al.: Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension, 2011, 58(2), 155–160.

  • Scholze, J., Bramlage, P., Trenkwalder, P., et al.: Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure. Expert Opin. Pharmacother., 2011, 12(18), 2771–2779.

  • Matsui, Y., O’Rourke, M. F., Hoshide, S., et al.: Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan combined treatment with olmesartan and a calcium-channel blocker versus olmesartan and diuretics randomized efficacy study. Hypertension, 2012, 59(6), 1132–1138.

  • Kékes, E.: Diurnal distribution of blood pressure and its consequences. Cardiovascular consequences of diurnal blood pressure variation. [A diurnalis vérnyomás-ingadozás és cardiovascularis következményei.] Orv. Hetil., 2002, 143(40), 2273–2277. [Hungarian]

  • Kékes, E.: Blood pressure variation and organ damage. [Vérnyomás-variabilitás és szervkárosodások.] Háziorvos Továbbképző Szemle, 2005, 10(4), 288–292. 57–61. [Hungarian]

  • Kékes, E.: Adequate management of cardiovascular risk reduction in hypertensive patients using combined treatment with antihypertensive, antilipid and anti-thrombocyta drugs. – The first year of the OPAL programme. [Hipertóniabetegségben a cardiovascularis rizikócsökkentés helyes megoldása kombinált antihipertenzív, antilipid és antitrombocitakezeléssel – Az OPAL-program egy éve.] Cardiol. Hung., 2010, 40(1), 14–19. [Hungarian]

  • Kékes, E.: Successful treatment of dyslipidemic hypertensive patients with fixed combination of amlodipine and atorvastatin (Amlator). [A fix kombinációban adott amlodipin/atorvastatin (Amlator) kezelés sikere dyslipidaemiás hypertoniás betegekben.] Hypertonia és Nephrologia, 2013, 17(1), 19–27. 243–245. [Hungarian]

  • Stergiou, G. S., Ntineri, A., Kollias, A., et al.: Blood pressure variability assessed by home measurements: a systematic review. Hypertens. Res., 2014, 37(6), 565–572.